GlassScriptPhysician profile
Howard M Gross
NPI 1023057148
$7,850.09
in general payments reported to CMS, 2019-2025
62 companies · $1,296 in 2025
The $1,296 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,168 · 2020: $212 · 2021: $417 · 2022: $894 · 2023: $1,940 · 2024: $1,922 · 2025: $1,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,956 · Education: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,956.44 |
| Education | $201.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $699.71 | 2021-2025 | Keytruda, Welireg, Reblozyl |
| Novartis Pharmaceuticals Corporation | $697.14 | 2019-2025 | |
| Abbvie INC. | $531.30 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $524.16 | 2019-2023 | Imbruvica, Epkinly |
| E.R. Squibb & Sons, L.L.C. | $491.51 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Janssen Biotech, INC. | $325.23 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $313.20 | 2021-2025 | Imfinzi, Enhertu, Calquence |
| Incyte Corporation | $308.02 | 2020-2025 | Jakafi, Pemazyre, Monjuvi |
| Gilead Sciences, INC. | $270.30 | 2022-2025 | Trodelvy |
| Pfizer INC. | $228.37 | 2019-2025 | |
| Celgene Corporation | $183.65 | 2019-2025 | Reblozyl, Pomalyst |
| Amgen INC. | $179.75 | 2019-2023 | Kyprolis, Blincyto |
| Daiichi Sankyo INC. | $171.94 | 2019-2025 | Enhertu, Injectafer |
| Regeneron Healthcare Solutions, INC. | $171.80 | 2019-2025 | Libtayo |
| Genmab U.S., INC. | $163.07 | 2023-2025 | Epkinly |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $153.26 | 2023-2025 | Orserdu, Elzonris |
| Lilly USA, LLC | $150.89 | 2020-2025 | Jaypirca, Verzenio, Retevmo |
| Genzyme Corporation | $139.40 | 2019-2024 | |
| Rigel Pharmaceuticals, INC. | $121.60 | 2019-2024 | Rezlidhia, Tavalisse |
| Takeda Pharmaceuticals U.S.A., INC. | $118.29 | 2022-2024 | Iclusig, Alunbrig, Fruzaqla |
| Eisai INC. | $113.16 | 2019-2024 | |
| Genentech USA, INC. | $112.16 | 2023-2025 | Polivy, Tecentriq Hybreza, Tecentriq |
| Ipsen Biopharmaceuticals, INC | $109.59 | 2021-2025 | Onivyde |
| Seagen INC. | $108.56 | 2020-2023 | Padcev, Tukysa |
| Alexion Pharmaceuticals, INC. | $98.52 | 2024 | Soliris, Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $96.91 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $95.29 | 2022-2025 | |
| Glaxosmithkline, LLC. | $79.54 | 2024-2025 | Ojjaara |
| Tersera Therapeutics LLC | $74.72 | 2021-2024 | Zoladex |
| Jazz Pharmaceuticals INC. | $74.41 | 2019-2024 | |
| Beigene USA, INC. | $70.88 | 2021-2025 | Brukinsa |
| Foundation Medicine, INC. | $60.12 | 2019-2023 | |
| Astellas Pharma US INC | $58.08 | 2019-2024 | Vyloy |
| Kyowa Kirin, INC. | $57.67 | 2024 | Poteligeo |
| Kite Pharma, INC. | $56.79 | 2022-2024 | Yescarta |
| Puma Biotechnology, INC. | $55.00 | 2019-2021 | |
| Exelixis INC. | $44.27 | 2021-2025 | Cabometyx |
| Sobi, INC | $42.30 | 2023-2025 | |
| Syndax Pharmaceuticals, INC. | $37.16 | 2025 | Revuforj |
| Karyopharm Therapeutics INC. | $34.37 | 2022-2023 | Xpovio |
| G1 Therapeutics, INC. | $33.79 | 2023 | Cosela |
| Blueprint Medicines Corporation | $33.69 | 2023 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.90 | 2019 | |
| Myriad Genetic Laboratories, INC. | $23.81 | 2024 | Myrisk |
| Morphosys, US INC. | $23.47 | 2023 | Monjuvi |
| Springworks Therapeutics, INC. | $22.56 | 2025 | Gomekli |
| Mirati Therapeutics, INC. | $21.99 | 2024 | Krazati |
| Pharmaessentia USA Corporation | $21.19 | 2023 | Besremi |
| Eusa Pharma (US) LLC | $20.39 | 2019 | |
| Array Biopharma INC | $20.31 | 2023 | Lorbrena, Braftovi |
| Deciphera Pharmaceuticals INC. | $19.73 | 2023 | Qinlock |
| Servier Pharmaceuticals LLC | $18.80 | 2024 | |
| Menarini Silicon Biosystems, INC. | $17.66 | 2023 | Cellsearch |
| Adc Therapeutics America, INC. | $17.53 | 2024 | |
| Legend Biotech USA INC. | $17.36 | 2025 | Carvykti |
| Apellis Pharmaceuticals, INC. | $17.18 | 2023 | Empaveli |
| Epizyme, INC. | $17.08 | 2021 | |
| Heron Therapeutics, INC. | $15.52 | 2019 | |
| Clovis Oncology, INC. | $13.76 | 2019 | |
| Dova Pharmaceuticals | $11.23 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.05 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.